4Gohda E, Tsubouchi H, et al. Nakayama H. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with hepatic failure. J Clin lnvest , 1988, 81(2): 414-419.
5Shimizu I , Ichihara A , Nakamura T , Hepatocyte growth factor in ascites from patients with cirrhosis. J Biochem Tokyo 1991,109(1) :14-18.
6Schirmacher P, Geerts A, Pietrangelo A. Hepatocyte growth factor/hepatopoietin A is expressed in fatstoring cells from rat liver but not myofibroblast-like cells deprived from fatstoring cells. Hepatology, 1992,15(1):5-11.
7Pictile KO, Harrnoincn AP, Jokinitity J, et al. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment [J]. Eur Heart J, 1996,17: 1345-1349.
8Sato T, Yoshinouchi T, Sugimoto T, et al. Prognostic value of serum hepatocyte growth factor in patients with acute coronary syndromes [J] .Jpen Circ J, 1999, 63.. 583-588.
9Tamura M, Arakaki N, Tsubouchi H, et al. Enhancement of human hepatocyte growth factor production by interlenkin-1 and Tumor necrosis factor-α by fibroblasts in cluture [J]. J Biol Chem, 1993, 268: 8140-8145.
10Heeschen C, Dimmeler S, Hamm CW, et al. Prognostic signifie.ance of angiogenic growth factor serum levels in patients with acute coronary syndromes [J]. Circulation, 2003, 107 (4):524-530.
